Friday, July 10, 2026

Drug profile · INN

siponimod fumaric acid

siponimod fumaric acid (MAYZENT) is a sphingosine 1-phosphate receptor edg-1 agonist.

PMDA: approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — siponimod fumaric acid
Class
Route
Patents
0
Programs
3
Data quality
0.78

Quick answer

siponimod fumaric acid (MAYZENT) is a sphingosine 1-phosphate receptor edg-1 agonist.

Key facts

INN siponimod fumaric acid
Brand MAYZENT
Mechanism Sphingosine 1-phosphate receptor Edg-1 agonist
Target Sphingosine 1-phosphate receptor 1

Mechanism of action

Sphingosine 1-phosphate receptor Edg-1 agonist

Primary target: Sphingosine 1-phosphate receptor 1

Approval history

Authority Status Date
PMDA approved

Pipeline programs

  1. CBAF312D2301 Phase 3 · Novartis India · Multiple Sclerosis in pediatric patients
  2. GR-2021-12373041 Approved · Théa Pharma Ireland · patients with secondary progressive MS
  3. SIPO20 Approved · Théa Pharma Ireland · Active progressive multiple sclerosis course after an initia

Related & competitor drugs

  1. ponesimod Antineoplastic and immunomodulating agents (L04)
  2. etrasimod arginine Sphingosine 1-phosphate receptor Edg-6 modulator
  3. ozanimod hydrochloride Sphingosine 1-phosphate receptor Edg-1 modulator
  4. siponimod Antineoplastic and immunomodulating agents (L04)
  5. etrasimod Antineoplastic and immunomodulating agents (L04)
  6. cenerimod Sphingosine 1-phosphate receptor Edg-1 modulator

Frequently asked questions

What is siponimod fumaric acid?

siponimod fumaric acid (MAYZENT) is a sphingosine 1-phosphate receptor edg-1 agonist.

What is the brand name for siponimod fumaric acid?

MAYZENT is a marketed brand name for siponimod fumaric acid. Check FDA Drugs@FDA for the current US label holder and prescribing information.